SCHEMBL4769062

SCHEMBL4769062

O=C(Cc1nc2ccccc2[nH]1)Nc1cc(-c2cccnc2)nc(-c2ccccn2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.46
ADRB3 P13945 1/20 0.46
ADORA2A P29274 4/20 0.44
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
IRAK4 Q9NWZ3 1/20 0.42
EGFR P00533 1/20 0.41
KDM4E B2RXH2 3/20 0.41
LDHA P00338 1/20 0.41
EPHX2 P34913 1/20 0.41
PDE10A Q9Y233 1/20 0.41
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HTT P42858 1/20 0.40
GBA1 P04062 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4770635 0.91 CYP1A2 (0.52) ADRB3ADORA2AALDH1A1TDP1IRAK4
SCHEMBL4775037 0.83 EGFR (0.42) EGFRKDM4ELDHAEPHX2SMN1; SMN2
SCHEMBL4773415 0.81 ADORA2A (0.43) ADORA2AALDH1A1KMT2AKDM4EMAPT
SCHEMBL4776165 0.81 CCKBR (0.52) ALDH1A1MEN1POLBKMT2AEGFR
SCHEMBL4774973 0.80 ADRB2 (0.46) ADRB2ADRB3ADORA2AALDH1A1MEN1
SCHEMBL4771758 0.79 ADORA1 (0.43) ADORA2APOLBKMT2ASMN1; SMN2HTT
SCHEMBL4766014 0.77 ADORA1 (0.47) ADORA2AALDH1A1POLBSMN1; SMN2HTT
SCHEMBL4773144 0.76 ADORA2A (0.47) ADORA2AALDH1A1KMT2AKDM4EMAPT
SCHEMBL5024997 0.76 ADORA2A (0.53) ADORA2AWNT1DYRK1AADORA1CYP1A2
SCHEMBL4769102 0.76 KMT2A (0.55) ADORA2AALDH1A1MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed